Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Rivaroxaban in Patients with CAT: A Pooled Meta-Analysis of 3 Randomized Controlled Trials

Silvy Laporte, Andrea Marshall, Annie Young, Hanno Riess, Marianne Sinn, Philippe Girard, Olivier Sanchez

Blood (2021) 138 (Supplement 1): 1068.

https://doi.org/10.1182/blood-2021-150748

Published: 2021

Journal Articles

GECAT - German Evaluation of Cancer Associated Thrombosis: A Prospective Register Trial for Patients with Active Cancer and Venous Thromboembolism (VTE) in Berlin

Marianne Sinn, Christiane Pollich, Hanno Riess, Sven Bischoff, Piet Habbel, Christian W Scholz, Ernst Spaeth-Schwalbe, Maike de Wit, Anja Jühling, Eike Wolter, Lilianna Wislocka, Dr. Klamroth

Blood (2019) 134 (Supplement_1): 4969.

https://doi.org/10.1182/blood-2019-128166

Published: 2019

Journal Articles

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Blood (2018) 132 (Supplement 1): LBA-1.

https://doi.org/10.1182/blood-2018-120738

Published: 2018

Journal Articles

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients

Blood (2015) 126 (23): 816.

https://doi.org/10.1182/blood.V126.23.816.816

Published: 2015

Journal Articles

Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

Ralf Trappe, MD, PhD, Stephan H.K. Oertel, MD, Veronique Leblond, MD, PhD, Peter Mollee, MBBS, MMedSc, Monica Sender, MD, Petra Reinke, MD, PhD, Ruth Neuhaus, MD, Hans Lehmkuhl, MD, PhD, Heinz A. Horst, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, Arnaud Jaccard, MD, PhD, Thierry Lamy, MD, PhD, Malte Leithäuser, MD, Ioannis Anagnostopoulos, MD, PhD, Martine Raphael, MD, PhD, Hanno Riess, MD, PhD, Sylvain Choquet, MD

Blood (2011) 118 (21): 878.

https://doi.org/10.1182/blood.V118.21.878.878

Published: 2011

Journal Articles

Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.

Blood (2009) 114 (22): 100.

https://doi.org/10.1182/blood.V114.22.100.100

Published: 2009

Journal Articles

Reduction of Immunosuppression and Subsequent Rituximab Monotherapy or CHOP-Based Chemotherapy +/− Rituximab as a Treatment for PTLD Does No Impair the Renal Graft Function: A Matched Pair Control Analysis in 55 Renal Transplant Recipients with PTLD and 1075 Renal Transplant Controls

Ulrike Appel, Carl Hinrichs, Petra Reinke, Nina Babel, Hans H Neumayer, Klemens Budde, Martin Dreyling, Ulrich Dührsen, Volker Kliem, Silke Schüttrumpf, Ingeborg A Hauser, Hans G Mergenthaler, Bernd Dörken, Ioannis Anagnostopoulos, Hanno Riess, Ralf Trappe, On behalf of the German Study Group on PTLD

Blood (2008) 112 (11): 3613.

https://doi.org/10.1182/blood.V112.11.3613.3613

Published: 2008

Journal Articles

Results of the Largest Study on Post-Transplant-Lymphoproliferations (PTLDs) of the Central Nervous System (CNS) in the Rituximab Era: A Surprising Overrepresentation of Kidney Transplantations, Key Importance of Methotrexate (Mtx), Cytarabine (AraC) and Radiotherapy (RX) for Long Term Survival and Low Impact of Rituximab (R)

Sylvain Choquet, Stefan Oertel, Ioannis Anagnostopoulos, Hanno Riess, Madalina Uzunov, V.éronique Leblond, Ralf Trappe

Blood (2008) 112 (11): 3614.

https://doi.org/10.1182/blood.V112.11.3614.3614

Published: 2008

Journal Articles

Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.

Ralf Trappe, MD, Sylvain Choquet, MD, Stephan Oertel, MD, Veronique LeBlond, MD, Tor Ekman, MD, Monica Sender, MD, Peter Molle, MD, Petra Reinke, MD, Hans Lehmkuhl, MD, Manfred Hummel, MD, Sven Jonas, MD, Ruth Neuhaus, MD, Gilles Salles, MD, Franck Morschhauser, MD, Arnaud Jaccard, MD, Daan Dierickx, MD, Ionannis Anagnostopoulos, MD, Martine Raphael, MD, Hanno Riess, MD

Blood (2007) 110 (11): 390.

https://doi.org/10.1182/blood.V110.11.390.390

Published: 2007

Journal Articles

Analysis of EBV-Specific T Cell Responses in Transplant Recipients with PTLD.

Kathrin Sebelin, Antje Meier, Matthias Papp-Vary, MD, Stefan Oertel, MD, Antonio Pezzutto, MD, Bernd Doerken, MD, Hanno Riess, MD, Marion Subklewe, MD

Blood (2005) 106 (11): 1915.

https://doi.org/10.1182/blood.V106.11.1915.1915

Published: 2005

Journal Articles

Sequential Treatment with the Anti-CD 20 Antibody Rituximab and CHOP+GCSF Chemotherapy in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD): First Interim Analysis of a Multicenter Phase II Study.

Ralf Trappe, MD, Stephan Oertel, MD, Sylvain Choquet, MD, Vernoique LeBlond, MD, Matthias Papp-Vary, Hanno Riess, MD

Blood (2005) 106 (11): 932.

https://doi.org/10.1182/blood.V106.11.932.932

Published: 2005

Journal Articles

Single Dose Per Cycle Pegfilgrastim Successfully Supports Full Dose CHOP-21 in Patients with Post-Transplant Lymphoproliferative Disorders (PTLD).

Matthias Papp-Vary, Stephan H.K. Oertel, MD, Georg Maschmeyer, MD, Hanno Riess, MD

Blood (2004) 104 (11): 4591.

https://doi.org/10.1182/blood.V104.11.4591.4591

Published: 2004

Journal Articles

Expression of Bomapin, a Novel Human Serpin, in Normal/Malignant Hematopoiesis and in the Monocytic Cell Lines THP-1 and AML-193

Matthias Riewald, Trinette Chuang, Andreas Neubauer, Hanno Riess, Raymond R. Schleef

Blood (1998) 91 (4): 1256–1262.

https://doi.org/10.1182/blood.V91.4.1256

Published: 1998

NARROW

Efficacy and Safety of Rivaroxaban in Patients with CAT: A Pooled Meta-Analysis of 3 Randomized Controlled Trials

GECAT - German Evaluation of Cancer Associated Thrombosis: A Prospective Register Trial for Patients with Active Cancer and Venous Thromboembolism (VTE) in Berlin

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients

Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.

Reduction of Immunosuppression and Subsequent Rituximab Monotherapy or CHOP-Based Chemotherapy +/− Rituximab as a Treatment for PTLD Does No Impair the Renal Graft Function: A Matched Pair Control Analysis in 55 Renal Transplant Recipients with PTLD and 1075 Renal Transplant Controls

Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.

Analysis of EBV-Specific T Cell Responses in Transplant Recipients with PTLD.

Sequential Treatment with the Anti-CD 20 Antibody Rituximab and CHOP+GCSF Chemotherapy in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD): First Interim Analysis of a Multicenter Phase II Study.

Single Dose Per Cycle Pegfilgrastim Successfully Supports Full Dose CHOP-21 in Patients with Post-Transplant Lymphoproliferative Disorders (PTLD).

Expression of Bomapin, a Novel Human Serpin, in Normal/Malignant Hematopoiesis and in the Monocytic Cell Lines THP-1 and AML-193

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only